The most promising AIDS vaccine in the pipeline was a bust -- and might actually have put participants in field tests at greater risk of becoming infected. Other trials of similar vaccines have also been called off, which raises an important question: is funding for AIDS vaccines a waste of money?
It also raises the question of where to direct funding for HIV/AIDS prevention. Should it go to long-shot vaccines or other, more proven prevention methods, like condom distribution and community awareness campaigns? The Washington Post reports that the National Institutes of Health directed $497 million of its annual budget towards AIDS vaccine research this year. That money could have bought a lot of condoms.
But the debate is a bit misguided. It’s unlikely that NIH funding or Big Pharma money aimed at finding a vaccine would ever be redirected toward prevention and education campaigns. Rather, the vaccine’s failure serves notice that a panacea is still years, if not decades away. And while research toward a vaccine continues -- as it should -- world leaders and the broader global public health community should be spurred by recent failures to recommit to existing prevention strategies.
You need to be logged in to comment.
(If there's one thing we know about comment trolls, it's that they're lazy)